1naresh2naresh<pre>Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [eb47f924-f49c-4984-9465-b87b14624b08] => Array
        (
            [runtime-id] => eb47f924-f49c-4984-9465-b87b14624b08
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [64a33bc9-df91-4fb7-87da-7d210e26e4b6] => Array
                        (
                            [runtime-id] => 64a33bc9-df91-4fb7-87da-7d210e26e4b6
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;1318899b8bd874fbdd07cc26139174d4dcf0fc96
                )

        )

)
1naresh2naresh<pre>Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [81d762d2-0a4c-4072-82eb-5654534645d0] => Array
        (
            [runtime-id] => 81d762d2-0a4c-4072-82eb-5654534645d0
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [bf058036-a07b-4ba7-ab30-a867648077f3] => Array
                        (
                            [runtime-id] => bf058036-a07b-4ba7-ab30-a867648077f3
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;1318899b8bd874fbdd07cc26139174d4dcf0fc96
                )

        )

)
PT  - JOURNAL ARTICLE
AU  - Ertl, L.
AU  - Holtmannspötter, M.
AU  - Patzig, M.
AU  - Brückmann, H.
AU  - Fesl, G.
TI  - Use of Flow-Diverting Devices in Fusiform Vertebrobasilar Giant Aneurysms: A Report on Periprocedural Course and Long-Term Follow-Up
AID  - 10.3174/ajnr.A3859
DP  - 2014 Jul 01
TA  - American Journal of Neuroradiology
PG  - 1346--1352
VI  - 35
IP  - 7
4099  - http://www.ajnr.org/content/35/7/1346.short
4100  - http://www.ajnr.org/content/35/7/1346.full
SO  - Am. J. Neuroradiol.2014 Jul 01; 35
AB  - BACKGROUND AND PURPOSE: Fusiform vertebrobasilar giant aneurysms are a rare (&amp;lt;1% of all intracranial aneurysms) but challenging aneurysm subtype. Little data are available on the natural history of this aneurysm subtype and the impact of the use of flow-diverting stents on the long-term clinical and imaging follow-up. In this article, we present our experience with the treatment of fusiform vertebrobasilar giant aneurysms by flow diverting stents. We aim to stimulate a discussion of the best management paradigm for this challenging aneurysm subtype. MATERIALS AND METHODS: We retrospectively identified 6 patients with fusiform vertebrobasilar giant aneurysms who had been treated with flow-diverting stents between October 2009 and March 2012 in our center. The available data were re-evaluated. The modified Rankin Scale score was assessed before intervention, during the stay in hospital, and at discharge. RESULTS: Six patients were identified (all male; age range, 49–71 years; median age, 60 years). Handling of material was successful in all cases. No primary periprocedural complications occurred. The mean follow-up was 13 months (15 days to 29 months). During follow-up, 3 of 6 patients had recurrent cerebral infarctions, but no patient experienced SAH. Two patients presented with acute thrombotic stent occlusion. The modified Rankin Scale score was not higher than 3 in any of the cases before intervention, whereas the best mRS score at the last follow-up was 5. Four of 6 patients died during follow-up. CONCLUSIONS: Endovascular treatment of fusiform vertebrobasilar giant aneurysms with flow-diverting devices is feasible from a technical point of view; however, changes in hemodynamics with secondary thrombosis are not predictable. We currently do not intend to treat fusiform vertebrobasilar giant aneurysms with flow-diverting devices until we have further understanding of the pathophysiology, natural history, and hemodynamic effects of flow diversion. ASAacetylsalicylic acidFVBGAfusiform vertebrobasilar giant aneurysm